Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Heather Hosack

Physician Assistant Wheat Ridge, CO Physician Assistant

NPI 1568713683 CMS profile 11156309

8550 W 38Th Ave Ste 220, Wheat Ridge, CO 80033

Open in the dashboard

General payments

$3,750

221 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heather Hosack of Wheat Ridge, CO is reported in the CMS Open Payments database as having received $3,750 across 221 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28 1
2023 General $568 28
2022 General $1,730 103
2021 General $1,425 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heather Hosack
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Heather Hosack were reported at $28. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Heather Hosack Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,425 $132 $37–$438 $132
2022 $1,730 $155 $48–$522 $149
2023 $568 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $28 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $734 47 payments
  2. AstraZeneca Pharmaceuticals LP $408 26 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $342 17 payments
  4. Merck Sharp & Dohme Corporation $162 10 payments
  5. Amgen Inc. $162 10 payments
  6. Lilly USA, LLC $159 12 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $141 8 payments
  8. Otsuka America Pharmaceutical, Inc. $129 9 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $113 6 payments
  10. E.R. Squibb & Sons, L.L.C. $102 5 payments
  11. Other $1,299 71 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,750 221 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $386 21 payments
  2. UBRELVY $290 21 payments
  3. FARXIGA $283 19 payments
  4. JARDIANCE $278 13 payments
  5. TRADJENTA $239 11 payments
  6. SYNJARDY $221 10 payments
  7. TRULICITY $146 11 payments
  8. Kerendia $129 7 payments
  9. REXULTI $129 9 payments
  10. NURTEC ODT $127 7 payments
  11. Other $3,340 197 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 73 drugs

Part D claims

2,174

Median for Physician Assistant: 241

Drug cost

$117,032

Median for Physician Assistant: $4,110

Branded share of claims

17.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 35 $26,256
Ozempic Semaglutide Brand 19 $20,433
Xarelto Rivaroxaban Brand 12 $17,008
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 18 $11,718
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 11 $7,885
Testosterone Generic 18 $5,108
Advair Hfa Fluticasone Propion/Salmeterol Brand 12 $3,334
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 12 $2,463
Albuterol Sulfate Hfa Albuterol Sulfate Brand 59 $1,740
Levothyroxine Sodium Generic 192 $1,552

The 10 drugs with the highest cost, of 73 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$18,330

Of which drugs: $1,627

Medicare patients

190

Average age 72

Services billed

716

121 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 44%
Chronic kidney disease 27%
Diabetes 25%
Ischemic heart disease 23%
Depression 21%
COPD 18%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record